These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37503786)

  • 1. Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.
    Affolter A; Liebel K; Tengler L; Seiz E; Tiedtke M; Azhakesan A; Schütz J; Theodoraki MN; Kern J; Ruder AM; Fleckenstein J; Weis CA; Bieback K; Kramer B; Lammert A; Scherl C; Rotter N; Ludwig S
    Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.
    Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z
    Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma.
    Xu S; Wang H; Zhu Y; Han Y; Liu L; Zhang X; Hu J; Zhang W; Duan S; Deng J; Zhang Z; Liu S
    Int J Oral Sci; 2024 Jul; 16(1):47. PubMed ID: 38945975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
    Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
    Front Immunol; 2019; 10():1206. PubMed ID: 31214178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.
    Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N
    Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
    Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
    Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
    Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
    Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
    Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
    Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and analysis of tumor‑derived extracellular vesicles from head and neck squamous cell carcinoma plasma by galectin‑based glycan recognition particles.
    Benecke L; Chiang DM; Ebnoether E; Pfaffl MW; Muller L
    Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
    Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
    Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
    Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC.
    Rong C; Muller MF; Xiang F; Jensen A; Weichert W; Major G; Plinkert PK; Hess J; Affolter A
    Br J Cancer; 2020 Jul; 123(2):288-297. PubMed ID: 32424150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.